-
Abstract Number: PB0561
Ca2+ and Zn2+ binding to human Protein Z (PZ) induces structural changes that augments its lipid binding
-
Abstract Number: OC 25.2
Cabozantinib Safety with Different Anticoagulants in Patients With Renal Cell Carcinoma (RCC)
-
Abstract Number: PB0881
Calcium-and integrin-binding protein 2 negatively regulates in vivo thrombosis and platelet functions by attenuating S1P production
-
Abstract Number: PB1034
Calcium-dependent monoclonal antibody against Gla-domain of protein S efficiently inhibiting both protein C and TFPI anticoagulant pathways
-
Abstract Number: PB0445
Calibration of the International Normalized Ratio dedicated to Rivaroxaban according to WHO guidelines
-
Abstract Number: PB1097
Can Low-molecular weight heparin calibrated anti-FXa assays be used to estimate Factor Xa inhibiting Direct Oral Anticoagulant levels?
-
Abstract Number: PB0483
Can Thrombin Generation Assay Predict Bleeding Risk in Patients with Severe Liver Failure?
-
Abstract Number: PB1142
Canadian Patient Experience on Switching from Octocog Alfa to Extended Half-Life FVIII Damoctocog Alfa Pegol in Patients with Severe Hemophilia A
-
Abstract Number: OC 31.3
Canadian prospective external validation of YEARS and age-adjusted pulmonary embolism testing
-
Abstract Number: PB0930
Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued
-
Abstract Number: VPB0759
Cancer-associated fibroblasts promote venous thrombosis through C-type lectin-like receptor 2/podoplanin in 3LL lung cancer mouse model
-
Abstract Number: PB0290
Caplacizumab for the management of acute immune-mediated thrombotic thrombocytopenic purpura: real world data from the Milan TTP Registry
-
Abstract Number: PB0302
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura: Comparative Real-world Multicenter Study
-
Abstract Number: OC 46.5
Carbamylation in acute ischemic stroke thrombi impairs t-PA-mediated thrombolysis and increases thrombus frailty
-
Abstract Number: OC 13.4
Cardio-embolic vulnerability predicts hospitalisation in primary care clinically suspected and confirmed COVID-19 patients: a model development and validation study
-
Abstract Number: PB1236
Carrier detection of Glanzmann Thrombasthenia by Flow Cytometry
-
Abstract Number: PO0056
Castatrophic Antiphospholipid Syndrome in a Young Woman
-
Abstract Number: PO0067
Catastrophic Antiphospholipid Syndrome in a 28 years old male: A case report
-
Abstract Number: PB0293
Cattle-FRETS71, a Novel Fluorogenic Substrate with Broad Applicability in Characterizing ADAMTS13 Properties and Function.
-
Abstract Number: OC 32.5
CD146-positive tumors are associated with venous thromboembolism
-
Abstract Number: OC 10.1
CD36-dependent metabolic rewiring and mitochondrial dysfunction in platelets in response to hyperlipidaemia.
-
Abstract Number: OC 68.4
CD39-Bearing Extracellular Vesicles Constrain Platelet Purinergic Signaling-Dependent Pulmonary Thrombosis in Sickle Cell Disease
-
Abstract Number: OC 57.3
Cell-based high throughput screening to identify FDA/EMA approved drugs that inhibit the endothelial pro-thrombotic switch during severe COVID19 infection
-
Abstract Number: PB0743
Cell-free DNA is increased in plasma of immunothrombotically dysregulated patients with periprosthetic joint infection in part due to lower DNaseI activity
-
Abstract Number: PB0262
Cerebral Sinovenous Thrombosis In Greek Children: A Single Centre Experience
-
Abstract Number: PB0266
Cerebral Venous Sinus Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Risk Factors and Long-Term Outcomes
-
Abstract Number: PB1332
Cerebral venous thrombosis: clinical, radiological, biological and etiological characteristics of a French Prospective Cohort: Comparison with ISCVT cohort
-
Abstract Number: PO0031
Challenges in managing of care in a child with non-severe haemophilia B
-
Abstract Number: PB1128
Challenges in the management of gynecological bleedings and pregnancies in a woman with severe haemophilia A
-
Abstract Number: PB1369
Challenges of Anticoagulation Management Service and Need of Establishing Pharmacist-Led Anticoagulation Clinic in Tertiary Care Teaching Hospital, Ethiopia: A Qualitative Study
-
Abstract Number: PB0478
Changes in circulating H3 Histone levels during Extracorporeal Membrane Oxygenation in patients with severe respiratory failure with correlation to haemostatic complications
-
Abstract Number: OC 61.3
Changes in fibrinolysis during Extracorporeal Membrane Oxygenation in critically ill adult patients
-
Abstract Number: PB0895
Changes in immature platelet fraction after major trauma: a prospective cohort study
-
Abstract Number: PB0152
Changes in Platelet Functionality and Morphology during Storage of Platelet Concentrates
-
Abstract Number: VPB1046
Changes in Prothrombin time, Activated partial thromboplastin time and Thrombin time Tests of Patients Administered with Different Types of Anticoagulant in Calabar Metropolis, Nigeria
-
Abstract Number: OC 51.2
Changes in VWF, ADAMTS13, and Complement in Preeclampsia, HELLP syndrome and Other Obstetric Complications: a Single Centre Observational Study.
-
Abstract Number: PB0750
Changes to platelet quality and function in Waldenstrӧm Macroglobulinaemia
-
Abstract Number: PB0452
Changing management of superficial vein thrombosis: a 5 year single site observational study
-
Abstract Number: PB1337
Changing Pattern of Venous Thrombosis events in 2021 associated with COVID in a teaching hospital
-
Abstract Number: PB0678
Changing Recombinant Factor VIII for Plasma-derived FVIII during Immune Tolerance Induction: Results from the Brazilian Immune Tolerance (BrazIT) Study
-
Abstract Number: PB1199
Changing treatment paradigm in second line treatment of adult ITP patients with the availability of TPO agonists: A retrospective study from a tertiary care center in India
-
Abstract Number: PB0796
Characterisation of 17 Novel Von Willebrand Factor Missense Mutations
-
Abstract Number: PB1049
Characterisation of anti-TFPI Kunitz domain 3 antibodies that selectively inhibit protein S cofactor function.
-
Abstract Number: PB1304
Characterising Endothelial Colony-Forming Cells in The Context Of HIV: People Living with HIV Have Elevated Endothelial Colony-Forming Cell Frequency
-
Abstract Number: PB0824
Characteristics and Clinical Burden Among Patients With von Willebrand Disease Eligible for Prophylaxis: Results From a Retrospective US Cohort Study
-
Abstract Number: PB1330
Characteristics and trends of venous thromboembolism – local experience
-
Abstract Number: VPB0128
Characteristics of Critically Ill COVID-19 Patients with Positive Heparin-Induced Thrombocytopenia Antibody
-
Abstract Number: VPB0978
Characteristics of the deep vein thrombosis of the upper limb
-
Abstract Number: OC 74.3
Characterization and dissection of new structural variants in FXI deficiency by nanopore sequencing.
-
Abstract Number: OC 73.4
Characterization of a novel anti-GPVI antibody in a humanized GP6 (hGP6KI) mouse model
-
Abstract Number: PB1307
Characterization of a Novel Genetic Variant in Family with Protein S Deficiency
-
Abstract Number: VPB0206
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
-
Abstract Number: VPB0837
Characterization of Cellular Pathogenic Mechanism of Type 1 von Willebrand Disease with A1500V mutation
-
Abstract Number: PB0530
Characterization of disseminated intravascular coagulation (DIC) in a murine model of fecal-induced peritonitis
-
Abstract Number: VPB0609
Characterization of TF positive small extracellular vesicles in SARS-CoV-2 infection
-
Abstract Number: OC 55.2
Characterization of the Factor VIII and LRP1 Interaction Suggests a Dynamic Binding Mode with Switching of Alternative Multiple Canonical Bivalent and Non-Canonical Electrostatic Contacts
-
Abstract Number: PB0370
Characterization of the human platelet glycome upon storage using tandem mass spectrometry
-
Abstract Number: PB0848
Characterization of the uric acid transporter URAT1 (SLC22A12) in platelets and megakaryocytes
-
Abstract Number: PB0396
Characterization of thrombogenic effects of platelet tyrosine phosphatase SHP2 inhibition using the allosteric inhibitor SHP099
-
Abstract Number: PB0788
Chloroacilhidroquinone AR-5820 Reduces the Platelet Activity by Inhibition of Mitochondrial Bioenergetics
-
Abstract Number: OC 48.1
Choice of Anticoagulation in Patients with Low Risk Antiphospholipid Syndrome
-
Abstract Number: PB0856
Chronic inflammation of the liver and bile ducts contributes to platelet hypoactivity and platelet-leukocyte aggregate formation in Mdr2-/- mice
-
Abstract Number: PB1325
Chronobiology of Acute Deep Vein Thrombosis: A 28 Year Study of Lower Extremity Duplex Ultrasounds
-
Abstract Number: PB0730
Circulating activated protein C levels are reduced in cancer patients, a novel contribution to tumorigenesis?
-
Abstract Number: PB0160
Circulating EV and platelet releasate proteomes mirror the hyperactive, pro-inflammatory state of COVID-19 patients and may be adjunctive markers of COVID-19 severity
-
Abstract Number: VPB0608
Circulating levels of podoplanin and CLEC-2 in COVID-19: an exploratory study
-
Abstract Number: VPB0791
Circulating miRNAs release predicts suboptimal response to aspirin in patients at high cardiovascular risk with and without type 2 diabetes mellitus
-
Abstract Number: OC 45.1
Circulatory microRNA-411-5p as a novel prognostic biomarker for major adverse cardiac events in patients with atrial fibrillation
-
Abstract Number: PB0291
Citrullination of plasma proteins in immune-mediated Thrombotic Thrombocytopenic Purpura and sepsis
-
Abstract Number: PB0794
Classification of Japanese patients with aHUS treated with eculizumab by a diagnostic scoring system
-
Abstract Number: PB0971
Clinical and echocardiographic variables associated with residual perfusion defects after pulmonary embolism
-
Abstract Number: VPB0436
Clinical and etiological features of vena cava thrombosis: 69 cases study
-
Abstract Number: VPB0418
Clinical and immunological features of antiphospholipid syndrome
-
Abstract Number: PB1205
Clinical and laboratory characteristics of adults with immune thrombocytopenia in a contemporary cohort in Austria
-
Abstract Number: PB1235
Clinical and mutational spectrum of inherited thrombocytopenia related to cytoskeleton protein defects.
-
Abstract Number: OC 43.3
Clinical and phenotypic presentation of patients with low VWF in the Milan Center
-
Abstract Number: PB0036
Clinical and serological follow up of VITT patients treated with heparin and alternative anticoagulation
-
Abstract Number: PB0089
Clinical assessment of coagulation hemostasis in liver cirrhosis associated with COVID-19
-
Abstract Number: OC 39.4
Clinical characteristics and management of children with severe factor VII deficiency- analysis of a United Kingdom cohort
-
Abstract Number: PB1201
Clinical Characteristics and Maternal/Neonatal Outcomes in Pregnant Women with Immune Thrombocytopenic Purpura: A Systematic Review
-
Abstract Number: PB0950
Clinical Correlation Between Lupus Anticoagulant (LA) and Thrombosis – Ampang Hospital Experience
-
Abstract Number: VPB1231
Clinical efficacy of rituximab in the treatment of adult immune thrombocytopenia: a single center data analysis
-
Abstract Number: PB0985
Clinical experience in factor Xa inhibitors´ reversal with prothrombin complex concentrate in emergency settings
-
Abstract Number: VPB0946
Clinical Impact of Thromboprophylaxis in Pancreatic Cancer Patients: data from ACT4CAT study
-
Abstract Number: PB0710
Clinical Manifestations and Bleeding Scores in Inherited Factor VII Deficiency; The first national report from Iran.
-
Abstract Number: OC 27.2
Clinical Outcomes Following Prophylaxis With Octocog Alfa in Patients With Moderate Hemophilia A: 8-Year Interim Read-out of the Real-world AHEAD International Study
-
Abstract Number: PB0684
Clinical Outcomes in Patients with Hemophilia A in Brazil: 3-years of Follow-up of the AHEAD International Study
-
Abstract Number: OC 08.5
Clinical Prediction Tool to Identify Children at Risk for Pulmonary Embolism
-
Abstract Number: PB0247
Clinical report of five young patients (3-26 months of age) with moderate or severe hemophilia A receiving emicizumab
-
Abstract Number: PB1317
Clinical series of patients with non-bacterial thrombotic endocarditis not associated with cancer or lupus anticoagulant/antiphospholipid antibodies.
-
Abstract Number: PO0057
Clinical spectrum of antiphospholipid syndrome in a second level general hospital.
-
Abstract Number: PB0662
Clinical Study of Adenovirus-Associated Viral Vector-Mediated Gene Therapy of Human Factor VIII in Severe and Moderately Severe Hemophilia A
-
Abstract Number: PB1393
Clinical timing of uterotonic medications, tranexamic acid (TXA), and blood transfusions in postpartum hemorrhage (PPH) management
-
Abstract Number: PB1076
Clinical utility of ISTH BAT and Thromboelastography in assessment of patients referred for evaluation of bleeding disorders
-
Abstract Number: VPB0963
Clinico-laboratory Findings in Patients with Hereditary Thrombophilia in the North-Western Region of Russia
-
Abstract Number: PB0619
Clot Collapse in Scanning Electron Microscopy (SEM)
-
Abstract Number: OC 76.5
Clot Destabilisation by the Inclusion of Fibrin with Truncations in the αC-region
-
Abstract Number: PB1096
Clot Time Ratio (CTR) in atrial fibrillation patients on rivaroxaban
-
Abstract Number: VPB0123
CLOT WAVEFORM ANALYSIS (CWA) PARAMETERS AS INDICATOR OF CoVID-19 OUTCOME
-
Abstract Number: PB1336
Clustering of coagulation factors in acute venous thromboembolism identifies clusters of thromboinflammatory and endothelial activation markers as independent predictors of recurrence and mortality.
-
Abstract Number: OC 76.4
CM-352 reduces rivaroxaban-associated ICH by mechanisms dependent on MMP-10 and fibrinolysis inhibition
-
Abstract Number: PB0957
Co-inheritance of protein C deficiency and homozygous factor V Leiden mutation: 10-year follow-up on a case with severe presentation.
-
Abstract Number: PB1058
Coag-Lysis assay, an automated and standardized combined turbidity plasma clot formation and lysis assay
-
Abstract Number: PB1109
Coaguchek® Pro II performance evaluation to assess direct oral anticoagulants action. The DOAC-Check study.
-
Abstract Number: VPB0208
Coagulant potential of emicizumab in child hemophilia A patients
-
Abstract Number: PB1042
Coagulation activation in newly diagnosed AML is regulated by the heme enzyme myeloperoxidase.
-
Abstract Number: PB0063
Coagulation Disorders in Pediatric Patients Hospitalized due to SARS-CoV-2 Infection
-
Abstract Number: OC 28.3
Coagulation factor XII induces persistent uPAR-integrin β1 signaling promoting DNA damage and senescence in diabetic kidneys
-
Abstract Number: OC 28.5
Coagulation FXI regulates endothelial cell barrier function by inducing VE-cadherin proteolysis in an ADAM10-dependent manner
-
Abstract Number: PB0744
Coagulation markers improve the diagnosis of periprosthetic joint infection: involvement of immunothrombosis
-
Abstract Number: PB0591
Coagulation parameters predict COVID-19-related thrombosis in a neural network with a positive predictive value of 98%
-
Abstract Number: VPB0614
Coagulopathy associated with COVID-19 (CAC)
-
Abstract Number: PB0236
Coinheritance of Combined Factor V and Factor VII Deficiency is Associated With a Mild Bleeding Phenotype in Patient With Non-Transfusion Dependent Thalassemia
-
Abstract Number: PB0212
Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy
-
Abstract Number: VPB0648
Combination Thrombolytic Therapy Using Electrohydraulic Radial and Focused Shock Waves in The Animal Model of Embolic Common Carotid Artery Occlusion
-
Abstract Number: PB0564
Combined Molecular Dynamics and Docking Studies on Direct Oral Anticoagulant Binding to Factor Xa Variants
-
Abstract Number: OC 06.3
Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: an international retrospective study of outcomes.
-
Abstract Number: VPB1390
Common risk factors for arterial and venous thrombosis and the recurrence rate in young non-pregnant women
-
Abstract Number: PO0014
Comorbidities of COVID-19 promote Hypofibrinolysis
-
Abstract Number: PB1084
Comparability Of Anti-Xa Assessments Using Alternate Calibration Curves In Patients Receiving Rivaroxaban And Apixaban Therapy
-
Abstract Number: PB0656
Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A
-
Abstract Number: OC 48.4
Comparative Effectiveness of Alternative Bridging Therapies for Subtherapeutic INR in Ambulatory Patients with Left Ventricular Assist Devices
-
Abstract Number: OC 21.5
Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring
-
Abstract Number: PB0153
Comparative Pharmacokinetics of Coagulation Factor VIII and IX Products Between Independently Developed and Web-based Population Pharmacokinetic Models
-
Abstract Number: PB0068
Comparative profiles of routine and specialized biomarkers of coagulopathy and endotheliopathy in moderate and severe COVID-19 disease : a prospective observational study
-
Abstract Number: PB0549
Comparative Studies on Clotting and Antiprotease Profile of Heparins of Ovine, Bovine and Porcine Origin
-
Abstract Number: VPB0567
Comparative Studies on the Interaction of Heparins from Various Origins with Heparin Cofactor II and Antithrombin
-
Abstract Number: PB1361
Comparing the proportion of medical and surgical hospital inpatients requiring pharmacological thromboprophylaxis using different risk assessment models: an observational cohort study
-
Abstract Number: PB0929
Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism
-
Abstract Number: VPB0637
Comparison between Intermittent Bolus versus Continuous Intravenous Infusion of Tranexamic Acid in Hematological Disorders with Thrombocytopenia (BRAVE Trial)
-
Abstract Number: PB0701
Comparison between Self-Administered and Clinician-Administered ISTH Bleeding Assessment Tool in RUNX1 Patient Population
-
Abstract Number: VPB1120
Comparison between the DOAC Dipstick test in urine and chromogenic substrate methods in plasma on patients treated with direct oral anticoagulants.
-
Abstract Number: PB0322
Comparison of 2 functional assays (HIMEA and HIPA) for the diagnosis of vaccine-induced immune thrombocytopenia and thrombosis (VITT) : a franco-greek collaborative study
-
Abstract Number: PB0785
Comparison of antiplatelet effects of small phenolic compounds
-
Abstract Number: PB0911
Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study
-
Abstract Number: PB0624
Comparison of fibrinogen concentrates to cryoprecipitate in restoring clot integrity and stability against fibrinolytic degradation
-
Abstract Number: PB0055
Comparison of five different PF4 dependant immunoassays in the diagnosis of Vaccine-induced Thrombotic Thrombocytopenia (VITT)
-
Abstract Number: PB0260
Comparison of heparin-induced thrombocytopenia workup and clinical characteristics between pediatric and adult patients
-
Abstract Number: VPB1230
Comparison of platelet function with different tyrosine kinase inhibitors treatment in chronic myeloid leukemia, in vivo and ex vivo studies
-
Abstract Number: PB1225
Comparison of platelets function in patients with JAK2V617F or CALR mutated myeloproliferative neoplasms
-
Abstract Number: PB0910
Comparison of standard vs low dose of direct oral anticoagulants for the secondary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies
-
Abstract Number: PB1386
Comparison of the ETP-based thrombomodulin assay versus the ETP-based APC resistance assay on the ST Genesia system
-
Abstract Number: PB0918
Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer
-
Abstract Number: OC 16.4
COMPASS versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-Small Cell Lung Cancer on Active Treatment with Chemotherapy and Immunotherapy.
-
Abstract Number: PB0738
Complement and Haemostasis: Effects of complement inhibitors in a microfluidic bleeding model
-
Abstract Number: OC 02.1
Complement Receptors Mediate Binding of Heparin-Induced Thrombocytopenia Immune Complexes to Fc Receptor Bearing Cells
-
Abstract Number: PB1043
Complementary roles of red blood cells and platelets in high-throughput whole-blood thrombin generation
-
Abstract Number: PO0040
Complex Bleeding Management – Multidisciplinary Approach
-
Abstract Number: PB0264
Composition of thrombi in pediatric ECMO circuits
-
Abstract Number: OC 77.5
Comprehensive analysis of human glycoprotein Ibα O-glycosylation.
-
Abstract Number: PB1171
Comprehensive Genotype and phenotype characterization in Non-severe Hemophilia A patients on assay discrepancies
-
Abstract Number: LB 01.2
Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial
-
Abstract Number: PB1385
Concurrent use of Tranexamic acid and hormonal therapy for the management of heavy menstrual bleeding in women
-
Abstract Number: PB0801
Conformational dynamics of plasma-derived von Willebrand factor recapitulate isolated A1 domain and autoinhibitory module
-
Abstract Number: OC 67.4
Congenital factor VII deficiency in a large cohort of Portuguese patients — molecular profiling, pathogenicity stratification and genotype-phenotype correlation
-
Abstract Number: PO0042
Congenital factor XIII deficiency: a case study
-
Abstract Number: PB1141
Congenital Haemophilia A with very low titre inhibitor, undetectable by routine methods and presenting with discrepant factor VIII assays post treatment with recombinant FVIII
-
Abstract Number: PB0404
Connexins are post-translationally modified in activated platelets; potential role of calpain
-
Abstract Number: OC 40.3
Consumption of On-demand Factor Concentrates and Bypassing Agents for Management of Breakthrough Bleeds with Fitusiran Prophylaxis in People with Haemophilia A or B: An Analysis of Two Phase 3 Studies
-
Abstract Number: VPB0328
Contactless dielectric spectroscopy for detection of platelet-activating antibodies
-
Abstract Number: PB0961
Continued Suspected Direct Oral Anticoagulant Interference on Thrombophilia Testing: Experience of a Reference Laboratory
-
Abstract Number: PB0058
Contribution of biology to the diagnosis and follow-up of VITT: a French multicentre experience.
-
Abstract Number: VPB1292
Contribution of isoproterenol in hemostatic alterations in vivo
-
Abstract Number: OC 13.2
Convalescent Plasma Therapy Does Not Increase the Risk of Thromboembolism in The Treatment of COVID-19: A Systematic Review and Meta-Analysis
-
Abstract Number: OC 02.2
Cooperation between PF4-specific antibodies in heparin-induced thrombocytopenia: a new mechanism potentially contributing to hypercoagulability and thrombosis
-
Abstract Number: OC 11.5
Correction of Coagulopathy in Trauma Haemorrhage – Still Room for Improvement. A Secondary Analysis of the ITACTIC trial
-
Abstract Number: VPB0122
CORRELATION OF CLOT WAVEFORM ANALYSIS (CWA) PARAMETERS WITH THE DAYS OF HOSPITALIZATION OF CoVID-19 PATIENTS
-
Abstract Number: VPB0170
Correlation of Factor VIII Activity Measured by One-Stage Clotting and Chromogenic Substrate Assays in a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)
-
Abstract Number: VPB0840
Correlation study between VWF: RCO ristocetin cofactor activity and ISTH-BAT in von Willebrand disease
-
Abstract Number: VPB0021
Correlations between oxidative stress, endothelial injury and coagulation activation in hypertensive patients with chronic kidney disease
-
Abstract Number: PB1155
Cost of factor concentrates in the Brazilian Protocol of Immune Tolerance Induction: preliminary results of the Co$tIT Study
-
Abstract Number: OC 60.3
Cost-effectiveness of performing reference ultrasonography in patients with deep vein thrombosis
-
Abstract Number: PB0009
Could Pharmacoinvasive Strategy Using Streptokinase Be an Alternative to Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction in Resource Poor Settings?
-
Abstract Number: PO0016
Covid 19 with Hematological presentation and complications that may lead to Stem cell transplant
-
Abstract Number: VPB0105
COVID-19 Coagulopathies – Highlights On 2020-2021 Reported Data
-
Abstract Number: PB0605
COVID-19 disease is associated with a hypofibrinolytic state driven by elevated plasminogen activator inhibitor-1 and its cofactor vitronectin
-
Abstract Number: PB0047
Covid-19 vaccination & Acquired Hemophilia A: the case of a middle aged woman
-
Abstract Number: PB1133
COVID-19 vaccination in patients with hemophilia: experience from a single center
-
Abstract Number: PB0643
COVID-19-associated hemostasis alterations and outcomes in acute ischemic stroke patients treated with intravenous thrombolysis
-
Abstract Number: PB1414
COVID-19-associated hemostasis alterations in pregnancy: a prospective, case-control study
-
Abstract Number: PB0361
Coxsackievirus B3 infection of CD34+ cells impairs megakaryocyte and platelet production through activation of Toll-like receptors 7 and 8
-
Abstract Number: OC 40.5
Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors
-
Abstract Number: PB0359
CRISPR genome editing coupled with optimized biomanufactured human platelets for molecular and functional investigation of platelet biogenesis.
-
Abstract Number: PB1272
CRISPR-Based Knockout Red Blood Cells as Tools to Study Red Blood Cell Surface Protein Involvement in Thrombosis
-
Abstract Number: OC 35.4
Critical Role for RapGEF2 in PKC-Rap1-Integrin Signaling in Platelets
-
Abstract Number: OC 11.1
Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and strength; results from a sub-study of the FEISTY trial
-
Abstract Number: PB1003
CT-001 is a Rapid Clearing Factor VIIa with Enhanced Hemostatic Activity and Safety in Mouse Models of Acute Bleeding
-
Abstract Number: PB0976
CTPA in pregnant women with suspected pulmonary embolism: effect on neonatal thyroid function
-
Abstract Number: VPB0350
Curcumin potentiates an inhibitory effect of cangrelor on platelets
-
Abstract Number: PB0955
Current knowledge on factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: a systematic review and meta-analysis
-
Abstract Number: PB0683
Current landscape of prophylaxis and tolerisation in patients with Haemophilia A in Australia
-
Abstract Number: PB0244
Current practice of monitoring joint health in children and adolescents with hemophilia in Germany, Austria and Switzerland (GAS)
-
Abstract Number: PB1257
Custodiol Solution Improves Hemocompatibility of Decellularized Liver Scaffold
-
Abstract Number: OC 63.5
Cytokine profile of patients with Acquired Hemophilia A (AHA) in a longitudinal study
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.